bimatoprost
Phase 2- Indications
- Glaucoma, Ocular hypertension
Company intelligence / Profile preview
SpyGlass Pharma
Aliso Viejo, California, United Stateslinkedin.com ↗
- Ownership
- Public · SGP
- Development stage
- Phase 2
01
Overview
The company completed enrollment in Phase I/II trials in November 2024. 18-month data showed 100% of patients remained off all topical IOP-lowering drops, all patients achieved an IOP reduction of more than 20% from baseline, and 96% of patients maintained an IOP ≤18 mmHg. The platform was well-tolerated with no product-related adverse events.[4][5]
- Therapeutic areas
- Ophthalmology
- Modalities
- Drug delivery platformControlled release drug delivery
- Industry
- Implantable Medical Devices
02
Drug pipeline
1 asset03
Financials
- Market cap
- $913.1M
- Total revenue
- $0
- Enterprise value
- $680.5M
Beyond the preview
Go deeper on SpyGlass Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SpyGlass Pharma.